

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

September 29, 2014

Via E-Mail
Alexander F. Cohen
Latham & Watkins LLP
555 Eleventh Street NW
Suite 1000
Washington, DC 20004

Re: Allergan Inc.

Schedule 14D-9, as amended

Response letter dated September 26, 2014

File No. 5-40724

Dear Mr. Cohen:

We have reviewed your letter listed above responding to our oral comments issued on September 23, 2014. We have the following additional comments:

- 1. We note the following statement in your response to comment 1 issued on September 23, 2014: "Specifically, with respect to the press reports regarding potential acquisition transactions, either no negotiations took place, or discussion commenced significantly prior to Valeant's offer." Clarify the "offer" to which you refer. Specifically, are you referencing the exchange offer commenced by Valeant Pharmaceutical on July 18, 2014? Or the earlier communications from Valeant proposing a business combination transaction, including its letter to the Board of Allergan in April 2014? We may have additional comments after we review your response.
- 2. See our last comment above. Please supplementally list in your response letter all negotiations or discussions that Allergan has engaged in since February 2014 concerning any of the types of transactions referenced in Item 1006(c)(1) (c)(3) of Regulation M-A. As to each, identify the parties and the form of the transaction discussed, when negotiations commenced and (where applicable) when they terminated and under what circumstances. To the extent communications began, were terminated and then were revived, so indicate. We may have additional comments after we review your response.

Alexander F. Cohen, Esq. Latham & Watkins LLP September 29, 2014 Page 2

If you have any questions regarding these comments or your filings in general, please contact me at (202) 551-3263.

Sincerely,

/s/ Christina Chalk

Christina Chalk Senior Special Counsel Office of Mergers and Acquisitions